Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Healios K.K.
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
There are reports that the US biotech is considering pricing its as-yet-unapproved mRNA-1273 at $25-30 a dose, a price which would double as both a prime and boost dose would be administered.
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Healios Riken, SighRegen K.K.
- Healios N.A. Inc.
- Organoid Neogenesis Laboratory Inc.